What Next for Pfizer's Medical Device Business
Executive Summary
It didn't take a crystal ball to foresee Pfizer's recent announcement that it is looking to exit the medical device business. But the question is, How? Finding a buyer for its diverse cardiovascular, orthopedics and urological businesses is slim. The concensus among industry executives: Pfizer will try spinning the businesses out into a public corporation, following a strategy Lilly used very successfully with Guidant Corp.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.